Payment overview · 2025
General Payments
$127.41
1 reported records · 1 companies
Healthcare provider profile · identity verified
Prabash Koneru, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1033306204
Verified facts
What the public records show
CMS Open Payments records show Prabash Koneru, M.D. received $127.41 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $127.41 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $127.41 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $127.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 54 |
| Metformin Hcl | Metformin Hcl | 326 | 49 |
| Gabapentin | Gabapentin | 228 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 24 |
| Simvastatin | Simvastatin | 158 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 23 |
| Januvia | Sitagliptin Phosphate | 148 | 21 |
| Donepezil Hcl | Donepezil Hcl | 143 | 13 |
| Lisinopril | Lisinopril | 142 | 25 |
| Losartan Potassium | Losartan Potassium | 140 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | suppressed |
| Nifedipine Er | Nifedipine | 130 | suppressed |
| Eliquis | Apixaban | 126 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 117 | suppressed |
| Mirtazapine | Mirtazapine | 113 | suppressed |
| Carvedilol | Carvedilol | 110 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 98 | 14 |
| Famotidine | Famotidine | 95 | 13 |
| Meloxicam | Meloxicam | 95 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | suppressed |
| Omeprazole | Omeprazole | 86 | 13 |
| Alendronate Sodium | Alendronate Sodium | 85 | suppressed |
| Ibuprofen | Ibuprofen | 83 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 79 | 23 |
| Memantine Hcl | Memantine Hcl | 79 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 12 |
| Levetiracetam | Levetiracetam | 78 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 78 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | suppressed |
| Ozempic | Semaglutide | 66 | 12 |
| Labetalol Hcl | Labetalol Hcl | 62 | suppressed |
| Atenolol | Atenolol | 61 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Glipizide | Glipizide | 58 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 57 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Haloperidol | Haloperidol | 51 | suppressed |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Furosemide | Furosemide | 49 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 47 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Jardiance | Empagliflozin | 46 | 12 |
| Ssd | Silver Sulfadiazine | 46 | 11 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | suppressed |
| Glimepiride | Glimepiride | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 17 |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 29 |
| Clozapine | Clozapine | 36 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | 11 |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 34 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Alogliptin | Alogliptin Benzoate | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Calcium Acetate | Calcium Acetate | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Admelog | Insulin Lispro | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 16 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Insulin Aspart | Insulin Aspart | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Doxepin Hcl | Doxepin Hcl | 19 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Calcipotriene-Betamethasone | Calcipotriene/Betamethasone | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Mitigare | Colchicine | 17 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Mesalamine Er | Mesalamine | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Clozapine Odt | Clozapine | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Budesonide Er | Budesonide | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $127.41 · 1 records | E.R. Squibb & Sons, L.L.C. | COBENFY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error